Photo credits
Where Chlordiazepoxide Fits
Chlordiazepoxide was the first benzodiazepine. Leo Sternbach, a chemist at Roche, synthesized it more or less by accident in the mid-1950s while working through a series of compounds he'd shelved years earlier; it reached the market as Librium in 1960. It launched the benzodiazepine era, displaced the barbiturates that had been the sedatives of choice through the 1950s (drugs that were heavily sedating, easy to overdose on, and lethal in the attempt), and opened the door for diazepam, alprazolam, and clonazepam to follow.
That history is most of why you still hear the name. In modern practice, chlordiazepoxide is a niche drug with one durable role left: managing alcohol withdrawal. Its long half-life (driven by a chain of long-lived active metabolites) makes for a smooth, self-tapering course that is well suited to detox and poorly suited to almost everything else. For chronic anxiety it has been supplanted by agents that are easier to dose and to stop. In the elderly and in liver disease, the very pharmacology that makes it good for detox makes it a liability.
Chlordiazepoxide is a long-acting benzodiazepine whose active metabolites give it a built-in taper: an asset in alcohol withdrawal, a liability almost everywhere else, and a near-contraindication in the old and the cirrhotic.
Almost everything true of benzodiazepines as a class is true of chlordiazepoxide: the GABA-A mechanism, the dependence and withdrawal, the cognitive and fall risks, the fatal synergy with opioids and alcohol, the interaction profile. This guide covers that shared class pharmacology and stays specific to chlordiazepoxide where the specifics matter: its long-acting active metabolites, its detox dosing, and the populations where you should reach for something else.
Part 1: Indications
Alcohol withdrawal: the modern indication
Benzodiazepines are the standard of care for alcohol withdrawal because they are cross-tolerant with alcohol at the GABA-A receptor: they substitute for alcohol's GABAergic effect and prevent the autonomic storm, seizures, and delirium tremens that abrupt cessation can produce in a physically dependent drinker. Chlordiazepoxide, diazepam, and lorazepam are all used this way; chlordiazepoxide and diazepam are the classic long-acting choices. Withdrawal symptoms of acute alcoholism are an FDA-labeled indication for chlordiazepoxide, alongside anxiety disorders (and short-term relief of anxiety symptoms) and preoperative apprehension and anxiety.
Why a long-acting agent for withdrawal? Because the long tail of active metabolites produces a gentle, self-tapering decline in benzodiazepine effect as the drug clears over days. That smooths the course and reduces breakthrough symptoms and rebound between doses: you get fewer peaks and troughs than with a short-acting agent, and the drug tapers itself as levels fall. For a patient with intact liver function going through detox, that is exactly the profile you want.
The long half-life is the feature here, not the bug. In a healthy liver, chlordiazepoxide's slow, metabolite-driven washout does much of the tapering for you. That same slow washout is why you avoid it in the elderly and the cirrhotic, where the drug and its metabolites stack up instead of clearing.
Anxiety: historical, largely supplanted
Chlordiazepoxide is still FDA-labeled for anxiety, and benzodiazepines as a class remain effective and fast-acting for anxiety in all its forms: GAD, panic, social anxiety, and the "mixed anxiety/depression" that fills real-world practice. But chlordiazepoxide is rarely the right benzodiazepine for chronic anxiety today: its long-acting metabolites accumulate with daily dosing and can produce creeping sedation and cognitive dulling over weeks, and there is nothing it does for anxiety that a better-characterized agent doesn't do more predictably. If a patient does need a standing long-acting benzodiazepine, clonazepam is the more common modern choice; if they need short-term or as-needed coverage, lorazepam is cleaner. Consider chlordiazepoxide for anxiety mostly a legacy use.
Other benzodiazepine-class uses
The class also treats insomnia, panic disorder, seizures, catatonia, akathisia, and acute agitation, and benzodiazepines can augment antidepressants for the "distress" symptoms of depression. Chlordiazepoxide is not the agent of choice for any of these. Where a benzodiazepine helps, pick the one whose kinetics fit the job.
Where benzodiazepines sit in the anxiety algorithm
As a class, benzodiazepines are not first-line for chronic anxiety disorders. The sequence is SSRIs/SNRIs and psychotherapy (CBT) first; a benzodiazepine is added when those fail or while waiting for an antidepressant to take effect, ideally with concurrent psychotherapy. The reasons are dependence, tolerance, cognitive and fall risk, and abuse potential, covered below. None of this is specific to chlordiazepoxide; all of it applies to it.
Who it's not for
- The elderly: avoid; it's a Beers-list agent (see Special Populations).
- Patients with significant hepatic impairment: avoid; prefer lorazepam or oxazepam.
- Patients on opioids: the combination is potentially fatal.
- Patients with active non-alcohol substance use disorder, or a history of sedative/benzodiazepine abuse: high misuse liability.
- Patients with untreated OSA or COPD: respiratory suppression risk.
- Pregnancy: avoid where possible.
Part 2: Mechanism
Benzodiazepines are positive allosteric modulators of the GABA-A receptor. GABA is the brain's principal inhibitory neurotransmitter; when it binds GABA-A, it opens a chloride channel, hyperpolarizes the neuron, and slows firing. Benzodiazepines bind a distinct modulatory site adjacent to the GABA binding site and enhance the receptor's response to the GABA that's already there: they don't open the channel themselves, they turbocharge native GABA. The net effect is broad CNS inhibition, which produces the anxiolytic, sedative-hypnotic, anticonvulsant, and muscle-relaxant effects.
Two receptor-subunit facts explain the side-effect profile. The alpha-1 subunit mediates sedation; the alpha-2 subunit mediates anxiolysis. Benzodiazepines act at both, so they calm anxiety and sedate. (The "z-drugs" like zolpidem act mainly at alpha-1, hence sedation with less anxiolysis.)
This also explains the alcohol-withdrawal rationale and the danger of combinations. Alcohol modulates GABA-A too (by a messier mechanism, not a clean lock-and-key), which is why a benzodiazepine can substitute for it in withdrawal. And it's why stacking a benzodiazepine on alcohol, or on opioids, is dangerous: the depressant effects on respiration are additive across mechanisms.
Part 3: Pharmacokinetics
The long metabolite tail is what defines this drug, so this is the section that matters most.
Onset and absorption
Oral chlordiazepoxide is absorbed from the small intestine over roughly 30 minutes to a couple of hours, with a relatively slow, gradual onset compared to the fast, sharp "hit" of diazepam. Diazepam's high lipophilicity gets it across the blood-brain barrier fast (rapid onset, but shorter clinical action as it redistributes into fat); chlordiazepoxide comes on more gently. That slower onset is part of why it's less reinforcing and less abused than the fast-hitting agents, and part of why it suits a scheduled detox regimen rather than an as-needed anxiety rescue.
Chlordiazepoxide takes several hours to reach peak blood levels, and levels then decline slowly over several days. Warn patients not to drive, especially around the peak.
The active metabolites: why the effect lasts for days
Chlordiazepoxide itself has a moderate half-life (on the order of hours to a day), but that number badly understates its duration of action, because it is metabolized in the liver (oxidation, CYP-mediated) into a series of active metabolites that are themselves long-lived:
- desmethylchlordiazepoxide →
- demoxepam →
- desmethyldiazepam (nordiazepam), a long-acting active metabolite with a half-life measured in days (it's the same metabolite diazepam produces) →
- and ultimately oxazepam.
The practical consequence: the effective half-life of a course of chlordiazepoxide, counting the metabolites, stretches well beyond the parent drug, into the range of a day to several days, and with repeated dosing these metabolites accumulate. That long effective half-life, and the accumulation it produces, is the most important pharmacokinetic fact about the drug.
Two clinical implications follow directly:
- In detox, accumulation works for you. The metabolite tail gives you a smooth, self-tapering benzodiazepine effect as the course winds down.
- In anyone who can't clear it well (the elderly, the cirrhotic), accumulation works against you. The parent drug and its long-acting metabolites stack up, and you get progressive oversedation, confusion, ataxia, and falls, sometimes days after the last dose change.
Chlordiazepoxide (and diazepam) undergo hepatic oxidation and generate long-acting active metabolites → they accumulate. Lorazepam, oxazepam, temazepam, the "LOT" drugs, are cleared by glucuronidation (phase II), have no active metabolites, and don't accumulate. In a failing liver or an old patient, the LOT drugs are the safe choice and chlordiazepoxide is not.
Dose equivalency
Using lorazepam as the standard reference:
| Drug | Approx. equivalent dose |
|---|---|
| Chlordiazepoxide | 25 mg |
| Diazepam | 10 mg |
| Lorazepam | 1 mg |
| Clonazepam | 0.5 mg |
| Alprazolam | 0.5 mg |
So roughly: 25 mg chlordiazepoxide ≈ 10 mg diazepam ≈ 1 mg lorazepam ≈ 0.5 mg clonazepam. Treat these as estimates (cross-tolerance among benzodiazepines is incomplete and equivalencies vary patient to patient), but they're the numbers to anchor a switch or a taper, and they're consistent with the standard "1 mg lorazepam = 10 mg diazepam = 0.5 mg clonazepam" class rule scaled to chlordiazepoxide.
Part 4: How to Dose
Alcohol withdrawalwithdrawal symptoms of acute alcoholismFDA labelIf given by mouth: 50–100 mg first, then repeat as needed until agitation is controlled, up to 300 mg per day.In practiceGenerally preferred: dose by CIWA-Ar score, giving a typical 25–100 mg only when the score crosses a threshold, commonly 8–10.
Before surgerypreoperative apprehension and anxiety2 rows
Older adults (geriatric)FDA label5 mg, 2–4 times daily, in geriatric patients or in the presence of debilitating disease.In practiceIf ever: monitored inpatient alcohol withdrawal, no alternative, dosed cautiously. If one must have a benzodiazepine: lorazepam or oxazepam, low dose.
Children (pediatric patients)FDA labelLowest dose first. 5 mg, 2–4 times daily; may be increased in some pediatric patients to 10 mg, 2–3 times daily. Not recommended under 6.
Stopping and taperingFDA labelTaper gradually. If withdrawal reactions develop, consider pausing the taper or increasing to the previous tapered dosage level, then slow the taper.In practiceAt least two weeks, preferably much longer; long-term users routinely need 3–6 months, sometimes a year or more.
Alcohol withdrawal
Two broad strategies, both benzodiazepine-class approaches applied with chlordiazepoxide as the agent. Note ranges below are typical; institutional protocols vary and should govern.
1. Symptom-triggered (CIWA-guided) dosing, generally preferred. Score the patient with the CIWA-Ar scale and give chlordiazepoxide only when the score crosses a threshold (commonly CIWA-Ar ≥ 8–10). A typical dose is 25–100 mg, repeated and re-scored at intervals until the patient is comfortable. Symptom-triggered protocols consistently use less total benzodiazepine and shorten treatment duration versus fixed schedules, because you medicate the withdrawal the patient actually has rather than the one you predicted. It requires a setting that can reliably do serial CIWA scoring (trained nursing).
2. Fixed-dose taper with PRN cover. Where reliable CIWA scoring isn't available, give a scheduled, tapering course, for example on the order of 50–100 mg every 6 hours on day 1 (keep the day's total within the label's 300 mg a day), then stepping the dose down over roughly 3–5 days (e.g. tapering by ~25% per day toward zero), with additional PRN doses for breakthrough symptoms. The long metabolite tail means the effective taper is gentler than the written schedule suggests. A front-loaded variant gives repeated moderate doses early until light sedation is achieved, then lets the long half-life carry the taper.
Whichever you use:
- Give thiamine before or with glucose in any alcohol-withdrawal patient (to prevent Wernicke's); not a chlordiazepoxide effect, but don't forget it.
- Reassess mental status and respiration before each dose. The endpoint is a calm, rousable patient, not a snowed one.
- This is a full-liver, monitored strategy. In cirrhosis, or in an older patient, switch to lorazepam and dose conservatively rather than letting chlordiazepoxide accumulate.
The reason chlordiazepoxide became a detox standard is the same reason it's dangerous in the wrong host. Its self-tapering metabolite tail is a gift in a 45-year-old with a healthy liver and a bad withdrawal. In a 75-year-old, or in Child-Pugh B/C cirrhosis, that tail becomes a slowly rising tide of sedation: use lorazepam instead.
Part 5: Side Effects
The benzodiazepine class has a generally benign side-effect profile, and chlordiazepoxide is no exception, with the caveat that its long-acting metabolites make the sedative and cognitive effects more likely to accumulate over days than with a short-acting agent.
Sedation and drowsiness
The most common effect. Usually mild and often eases over a few days as tolerance to sedation develops; reassure patients of this. But with chlordiazepoxide, watch for creeping daytime sedation from metabolite accumulation, especially in the first couple of weeks of standing use or in anyone who clears the drug slowly.
Cognitive impairment
Benzodiazepines impair memory formation, processing speed, and attention. It's often subtle and insidious: it accumulates over months and neither patient nor prescriber attributes it to the drug. Many long-term users describe an "awakening" of clear-mindedness after they finally come off. Long-acting agents with accumulating metabolites are more prone to this. Consider periodic taper trials to unmask occult cognitive effects.
Falls
A major concern in older adults: pooled analyses put the odds of a fall in benzodiazepine users at roughly 1.4 to 1.6 times those of non-users, with risk highest in the first weeks of treatment. Long-acting, accumulating agents like chlordiazepoxide are worse offenders. Hip fractures in the elderly can be fatal.
Motor / driving impairment
Increased motor-vehicle-accident risk, dose-dependent, worst at peak levels but present on steady doses too. Patients are usually unaware of the impairment.
Respiratory suppression
Modest with a benzodiazepine alone at therapeutic doses, but a real hazard in OSA or COPD, and the mechanism behind the fatal combination with opioids and alcohol (see Overdose).
Paradoxical disinhibition
Uncommon, but documented across the class: agitation, aggression, or impulsivity instead of calm. More likely in the elderly, the cognitively impaired, and patients with borderline or antisocial personality disorder; use caution in those groups.
Part 6: Dependence, Tolerance, and Withdrawal
This is a class property, and it is central. Every benzodiazepine, chlordiazepoxide included, produces physiologic dependence if taken at a high-enough dose for more than a few weeks (typically 3–6 weeks of regular use).
A few distinctions worth making explicit to yourself and to patients:
- Dependence ≠ addiction. Dependence means the body has adapted and abrupt cessation will cause withdrawal. It is expected and physiologic, not evidence of "drug-seeking."
- Tolerance develops to sedation, usually not to the anxiolytic effect. That's reassuring for efficacy, but it also means patients who chase full symptom relief can escalate the dose without real benefit.
- Withdrawal, not relapse. Patients coming off often can't tell withdrawal symptoms from a return of their original anxiety. Educate them up front that the two feel alike, and that feeling bad on withdrawal is not proof they "need" the drug.
Withdrawal severity spans a wide range. Mild-to-moderate: rebound anxiety, insomnia, irritability, muscle tension, tremor, sweating, perceptual changes, tinnitus, paresthesias. Severe and rare (mainly in high-dose, abrupt cessation, or with concurrent alcohol/other drugs): seizures, delirium, psychosis, catatonia, and withdrawal akathisia, a severe inner restlessness that carries suicide risk. Serious withdrawal is uncommon in patients who took ordinary therapeutic doses without adding alcohol or illicit drugs.
Post-acute withdrawal syndrome (PAWS). Some patients have protracted symptoms (anxiety, cognitive fog, tinnitus, paresthesias, mood lability) that persist well beyond the 4–6 week acute phase, sometimes for months. It's real, often mistaken for relapse or a new disorder, and best prevented by tapering slowly in the first place. There is no reliable rescue once it sets in.
Because of its long half-life, it is sometimes used as the substitution agent to get a patient off a shorter-acting benzodiazepine: you convert to an equivalent chlordiazepoxide dose and taper the long-acting drug, whose smooth decline is easier to come off. This is the same logic as the traditional diazepam cross-taper. It's a reasonable tool, but current thinking cautions against automatically switching everyone to a long-acting agent to taper (accumulation risk, especially in the old and hepatically impaired); often it's cleaner to taper the agent the patient is already on.
Part 7: Discontinuation and Tapering
The governing rule for the whole class: never stop a chronically dosed benzodiazepine abruptly; taper slowly.
- Minimum taper: at least two weeks, and preferably much longer. Long-term users routinely need 3–6 months, and sometimes a year or more.
- Go faster over the first ~50% of the dose, then much slower over the last 50%: the low end is where withdrawal bites hardest. A common shape is roughly 10% per week early, decelerating as the dose gets small (a hyperbolic taper), or the standard "reduce ~25% every 2 weeks, then 12.5% near the end."
- Don't have the patient skip doses to taper; that causes blood-level swings and withdrawal, worse with shorter-acting agents. Reduce the daily dose consistently instead.
- For fine reductions, liquid formulations, pill-splitting, or compounded doses let you make sub-tablet steps.
- Chlordiazepoxide's own long half-life makes its taper relatively forgiving: the metabolite tail cushions the decline between reductions, an advantage of the drug for coming off in a patient who can clear it.
- No medication reliably treats benzodiazepine withdrawal. Adjuncts with some evidence: propranolol, pregabalin, carbamazepine, gabapentin, none strong. CBT for insomnia (CBT-i) is as effective as a benzodiazepine for sleep and is worth deploying alongside the taper.
Make it a joint project. Tapers fail when the prescriber wants discontinuation and the patient wants continuation: the resulting anxiety sabotages the effort. Explain the why (better cognition, mood, fewer falls), reassure that the pace will flex to what the patient can tolerate, and write the schedule down.
Part 8: Overdose and Safety
Benzodiazepines alone are among the safest drugs in psychiatry in overdose. A pure chlordiazepoxide overdose typically produces deep sedation, ataxia, slurred speech, and confusion, but respiration is usually preserved, unlike the barbiturates it replaced. Supportive care is usually enough.
The lethal scenario is combination. With opioids, alcohol, or other sedative-hypnotics, respiratory depression becomes additive across mechanisms and can be fatal. This is the origin of the opioid prong of the FDA boxed warning.
All benzodiazepines carry an FDA boxed warning covering:
- Concomitant use with opioids: profound sedation, respiratory depression, coma, death.
- Abuse, misuse, and addiction: can lead to overdose or death.
- Dependence and withdrawal: continued use can produce clinically significant physical dependence, and abrupt discontinuation or rapid dose reduction can precipitate acute withdrawal reactions that can be life-threatening.
Flumazenil is not a routine antidote. Flumazenil is a competitive GABA-A benzodiazepine-site antagonist that reverses benzodiazepine effect, but it is not safe for routine or home use. In a chronically dosed or dependent patient it can precipitate withdrawal seizures, and it can worsen outcomes in mixed overdoses (e.g. with a proconvulsant co-ingestant). Reserve it for monitored settings. In a combined overdose of a benzodiazepine and an opioid, naloxone is the agent that saves the patient by reversing the opioid; consider co-prescribing it for any patient on chronic opioids.
Part 9: Drug Interactions
Two categories: pharmacokinetic (levels) and pharmacodynamic (additive CNS depression). The second is the dangerous one.
Pharmacodynamic: additive CNS/respiratory depression
- Opioids: the big one. 2–4× increased overdose-fatality risk with concurrent benzodiazepines; black-box warning. If co-prescribing is unavoidable: one prescriber, check the PDMP, minimal doses, a treatment agreement, and consider naloxone. Avoid the combination altogether in patients ≥65, with respiratory disease, with a substance-misuse or overdose history, or on high opioid doses. Active opioid use disorder is a contraindication.
- Alcohol: synergistic depression; fatal at high combined levels, and increased accident risk at moderate ones. Note the paradox specific to chlordiazepoxide's main indication: you use it to treat alcohol withdrawal, but you must not have the patient drinking on top of it.
- Other CNS depressants: sedating antipsychotics, muscle relaxants (baclofen, cyclobenzaprine), gabapentinoids, sedating antihistamines, TCAs. Additive; less lethal than opioids but real.
Pharmacokinetic: drugs that raise chlordiazepoxide levels
Chlordiazepoxide is oxidatively metabolized (CYP3A4 and CYP2C19), so it is subject to the same interactions as the other oxidized benzodiazepines:
- CYP inhibitors raise levels: fluoxetine, fluvoxamine, oral contraceptives, grapefruit juice, and others. Disulfiram reduces benzodiazepine clearance and raises levels, which matters because a patient being treated for alcohol use disorder may be on it. Cimetidine likewise inhibits metabolism. When an inhibitor is on board, expect more sedation and accumulation; reduce the dose.
- CYP inducers lower levels: carbamazepine and other enzyme inducers.
Chlordiazepoxide inherits every oxidative-metabolism interaction the LOT drugs are immune to. If a patient's regimen is a minefield of CYP inhibitors or inducers, or their liver is compromised, that alone is a reason to prefer lorazepam or oxazepam, which sidestep CYP entirely via glucuronidation.
Part 10: Special Populations
Elderly: avoid (Beers list)
Benzodiazepines as a class are on the AGS Beers Criteria list of potentially inappropriate medications in older adults, and chlordiazepoxide is among the worst choices in the class. The reasons compound:
- Increased CNS sensitivity to sedation and cognitive impairment.
- Falls and fractures, traffic accidents, delirium.
- Accumulation: older patients have more body fat and slower clearance, so a long-acting, actively-metabolized agent like chlordiazepoxide builds up. Morning grogginess, "it takes me three hours to get dressed," going back to bed after breakfast: these are signs of hidden benzodiazepine toxicity in the elderly.
If an older patient must have a benzodiazepine, use lorazepam or oxazepam at a low dose: short-acting, no active metabolites, no accumulation. Reserve chlordiazepoxide's use in this group, if ever, for a monitored inpatient alcohol withdrawal where nothing else is available, and even then dose cautiously.
Hepatic impairment: avoid
Chlordiazepoxide depends on hepatic oxidation and generates long-acting active metabolites. In significant liver disease, both parent drug and metabolites accumulate, and you can oversedate a patient who is already at risk for hepatic encephalopathy. Prefer the LOT drugs (lorazepam, oxazepam, temazepam), which are cleared by glucuronidation, a pathway relatively preserved in liver disease, with no active metabolites.
For alcohol withdrawal in a patient with cirrhosis, don't use chlordiazepoxide; use lorazepam or oxazepam. Chlordiazepoxide is a fine detox agent in an intact liver, but the population most likely to be withdrawing from alcohol is also the population most likely to have the liver disease that makes chlordiazepoxide dangerous. Match the drug to the liver.
Pregnancy and lactation
Avoid benzodiazepines in pregnancy where you can. First-trimester exposure has been linked (on conflicting, mostly older data) to oral clefts; the association is weak but taken seriously, and later exposure risks neonatal sedation and withdrawal ("floppy baby"). If a benzodiazepine is unavoidable, short-acting agents with no active metabolites (lorazepam) are theoretically preferable to a long-acting, accumulating agent like chlordiazepoxide: the same logic that governs the elderly and the cirrhotic applies to the fetus. For breastfeeding, lorazepam is the better-characterized low-transfer choice; avoid long-acting agents that accumulate in the infant.
Substance use
Active non-alcohol substance use disorder and a history of sedative/benzodiazepine misuse are contraindications or strong cautions, though chlordiazepoxide's slow onset makes it less reinforcing and less abused than the fast-hitting agents (diazepam, alprazolam). The one substance-use context where it is useful is the acute treatment of alcohol withdrawal, under supervision.
Respiratory disease
Untreated OSA and COPD raise the stakes on benzodiazepine respiratory suppression; use the lowest dose with monitoring, or avoid.
Part 11: Chlordiazepoxide vs. Other Benzodiazepines
vs. Lorazepam / oxazepam (the LOT drugs). This comparison decides most cases. LOT drugs are glucuronidated, have no active metabolites, don't accumulate, and carry no CYP interactions, which makes them the correct choice in the elderly, in hepatic impairment, and in polypharmacy. Chlordiazepoxide's advantage over them is the smooth self-taper of its metabolite tail in a patient who can clear it, useful in detox and in coming off a benzodiazepine, but only when the liver and age are on your side. In cirrhotic alcohol withdrawal, lorazepam wins; in healthy-liver alcohol withdrawal, chlordiazepoxide is a fine, self-tapering option.
vs. Diazepam. The two are pharmacological cousins: both long-acting, both oxidized, both producing desmethyldiazepam and accumulating. Diazepam has a faster, sharper onset (higher lipophilicity), which makes it feel more rewarding and gives it slightly higher abuse liability; chlordiazepoxide's gentler onset is a mild advantage for a detox or dependence-prone context. For most withdrawal purposes they are interchangeable choices governed by local protocol.
vs. Clonazepam. Clonazepam is the more common modern choice when a standing long-acting benzodiazepine is wanted for anxiety or panic. It too is long-acting and accumulates (also Beers-listed, also to be avoided in the elderly), but it's better characterized for chronic psychiatric use than chlordiazepoxide, which has drifted almost entirely to detox.
vs. Alprazolam. Alprazolam is short-acting, fast-hitting, highest in abuse and overdose liability, and hard to taper: close to the opposite profile. It does not compete for chlordiazepoxide's use cases.
The Bedside Cheat Sheet
What it is
- The first benzodiazepine (Librium, 1960). Long-acting. GABA-A positive allosteric modulator.
- Modern role: alcohol withdrawal. For chronic anxiety, largely supplanted.
The defining pharmacology
- Hepatic oxidation → long-acting active metabolites (desmethylchlordiazepoxide → demoxepam → desmethyldiazepam → oxazepam) → accumulates.
- Great for detox (self-tapering); bad in the elderly and liver disease (stacks up).
Equivalency
- 25 mg chlordiazepoxide ≈ 10 mg diazepam ≈ 1 mg lorazepam ≈ 0.5 mg clonazepam (estimates).
Alcohol-withdrawal dosing
- Symptom-triggered (CIWA-guided), preferred: 25–100 mg when CIWA-Ar ≥ ~8–10, re-score and repeat. Uses less total drug, shorter course.
- Fixed taper: ~50–100 mg q6h day 1 (day's total within the label's 300 mg), taper over ~3–5 days, PRN for breakthrough.
- Give thiamine. Endpoint = calm and rousable, not snowed. Full-liver strategy only.
Class risks (all apply)
- Sedation, insidious cognitive impairment, falls, driving impairment, paradoxical disinhibition.
- Dependence within weeks; never stop abruptly. Taper ≥2 weeks, months for long-term users; slow at the end.
- Withdrawal = rebound anxiety/insomnia → (rarely) seizures/delirium/akathisia. PAWS can persist.
Safety
- Benign alone in overdose; fatal with opioids or alcohol (additive respiratory depression; black-box warning).
- Flumazenil reverses it but can trigger withdrawal seizures: monitored settings only; naloxone is what saves a benzo-opioid overdose.
Interactions
- Additive with opioids/alcohol/CNS depressants. CYP3A4/2C19 substrate: fluoxetine, fluvoxamine, disulfiram, cimetidine, OCPs raise levels; carbamazepine lowers them.
Populations
- Elderly: avoid (Beers). Hepatic impairment: avoid, use lorazepam/oxazepam. Pregnancy: avoid. Active non-alcohol SUD: avoid.
- Long half-life via active metabolites: an asset in alcohol withdrawal with a healthy liver, a liability in the old and the cirrhotic, where you switch to a LOT drug.
Chlordiazepoxide was the compound that ended the barbiturate age and started the benzodiazepine one, and six decades later it survives mainly because its long, metabolite-driven tail makes for a smooth alcohol detox in a patient with a working liver. The tail explains the rest of the drug. It is what makes chlordiazepoxide good at withdrawal and at coming-off tapers, and it is what makes it the wrong benzodiazepine for the elderly and the cirrhotic, the very patients most likely to cross your path in withdrawal. Reach for it when the liver is intact and the goal is a self-tapering course; reach for lorazepam or oxazepam when it isn't. Everything else about it is the benzodiazepine class: fast, effective, dependence-forming, dangerous with opioids and alcohol, and to be tapered, never yanked.